News >

Pembrolizumab Plus Lenvatinib Active in Endometrial Cancer

Angelica Welch
Published: Friday, Jul 06, 2018

Vicky Makker, MD

Vicky Makker, MD

The incidence of endometrial cancer continues to rise in the United States. The prognosis for patients in the recurrent and advanced settings is particularly poor, said Vicky Makker, MD, and options remain limited.

, Makker, who was also lead author of the study, discussed the combination and the future of endometrial cancer treatment.

OncLive: What was the rationale to explore the combination of lenvatinib and pembrolizumab in endometrial cancer?

Makker: Endometrial cancer is the most common gynecologic malignancy in the United States. The problem with this cancer type is that compared with other gynecologic cancers, the incidence and mortality of this disease is sharply on the rise. When they are early stage, endometrial cancers can often be cured and have a very good prognosis. However, in the recurrent or advanced settings, the prognosis is very poor. The other limitation is that, unlike other cancers, we don't have a lot of options in terms of treatment. This is particularly true for what we call the microsatellite-stable (MSS) population, which makes up the majority of the recurrent cases in this cancer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication